Other health risks include: Pancreatitis: Some studies suggest a possible link between GLP-1s and inflammation of the pancreas, though the risk appears to be low
Maa T, Bayley CP, Mrgelin M, Lettmann S, Bonaldo P, Paulsson M, et al
The therapeutic potential of glucagon-like peptide-1 for alcohol use disorder: A review
The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis
The most common side effects are: Nausea Vomiting Constipation Mild diarrhea Indigestion These are usually temporary and improve with gradual dose escalation
In a recent study of 79 individuals with history of coronary artery disease prior to pregnancy, there were low rates of cardiac events during pregnancy in all individuals with and without diabetes but more frequent poor obstetric and neonatal outcomes including SGA, HDP, and preterm delivery
